LYSOGENE: Lysogene continues to extend its pipeline | | EUR11
Lysogene announced that it exercised its option to in-license a program from Weizman institute in order to develop new gene therapycandidates targeting CNS diseases with GBA1 mutations. (Gaucher and Parkinson’s diseases).
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.